Synthesis and α-adrenergic and I1-imidazoline activity of 3- phenylpiperidines dimethyl-substituted on the phenyl ring

European Journal of Medicinal Chemistry

Volumn 33, Issue 11, 1998, Pages 911-919

  Macchia, Bruno ^a   Bylund, David B ^b   Calderone, Vincenzo ^a   Giannaccini, Gino ^a   Lucacchini, Antonio ^a   Macchia, Marco ^a   Martinelli, Adriano ^a   Martinotti, Enrica ^a   Orlandini, Elisabetta ^a   Romagnoli, Federico ^a   Rossello, Armando ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

3 phenylpiperidine derivatives; Conformational analysis; Imidazoline I1 receptor; 1 adrenergic receptor; 2 adrenergic receptor

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; HYDROXYL GROUP; IMIDAZOLINE DERIVATIVE; IMIDAZOLINE RECEPTOR; METHYL GROUP; PHENETHYLAMINE; PIPERIDINE DERIVATIVE;

ANIMAL TISSUE; ARTICLE; CALCULATION; CHEMICAL STRUCTURE; CONFORMATION; CONTROLLED STUDY; IN VITRO STUDY; ISOMER; LIGAND BINDING; NONHUMAN; RAT; SYNTHESIS;

EID: 0032299940     PISSN: 02235234     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0223-5234(99)80016-6     Document Type: Article

References (33)

1. [1] Macchia B., Macchia M., Martinelli A., Martinotti E., Orlandini E., Romagnoli F., Scatizzi R., Eur. J. Med. Chem. 32 (1997) 231-240.
2. [2] Weiner N., In: Gilman A.G., Goodman L.S., Rall T.W., Murad F. (Eds.), Drugs that Inhibit Adrenergic Nerves and Block Adrenergic Receptors; Pharmacological Basis of Therapeutics, Pergamon Press, New York, USA, 1985, pp. 181-214.
3. [3] Doze D.A., Chen B.X., Maze M., Anesthesiology 71 (1989) 75-79.
4. [4] Savola J.M., Virtanan R., Eur. J. Pharmacol. 195 (1991) 193.
5. [5] Bylund D.B., Eikenberg D.C., Hieble J.P., Langer S.Z., Lefkowitz R.J., Minneman K.P., Molinoff P.B., Ruffolo Jr. R.R., Trendelenburg A.U., Pharmacol. Rev. 46 (1994) 121-136.
6. [6] Parini A., Moudanos C.G., Pizzinat N., Lanier S.M., Trends Pharmacol. Sci. 17 (1996) 13-16.
7. [7] Flamez A., Gillard M., Backer J.P., Vauquelin G., Noyer M., Neurochem. Int. 31 (1997) 125-129.
8. [8] Macchia B., Macchia M., Manera C., Martinotti E., Nencetti S., Orlandini E., Rosselio A., Scatizzi R., Eur. J. Med. Chem. 30 (1995) 869-880.
9. [9] Venanzi L.M., J. Chem. Soc. (1958) 719-724.
10. [10] Julliard M., Siv C., Vernin G., Metzger J., Helv. Chim. Acta 61 (1978) 2941-2948.
11. [11] Aliprantis A.O., Canary J.W., J. Am. Chem. Soc. 116 (1994) 6985-6986.
12. [12] Julia M., Millet B., Bagot J., Bull. Soc. Chim. 3 (1968) 987-999.
13. [13] Lehmann J., Koening-Berard E., Vitou P., Life Sci. 45 (1997) 1609-1615.
14. [14] Insight II Version 2.3; Discover Version 2.9.5, Biosyn Technologies, San Diego, USA.
15. [15] Liljefors T., Wikström H., J. Med. Chem. 29 (1986) 1896-1904.
16. [16] Rollema H., Mastebroek D., Wikström H., Svensson K., Carlsson A., Sundell S., J. Med. Chem. 29 (1986) 1889-1895.
17. [17] Kenakin T.P., Pharmacol. Rev. (1984) 165-222.
18. [18] De Bernardis J.F., Winn M., Arendsen D.L., Kerkman D.J., Kyncl J.J., J. Med. Chem. 29 (1986) 1413-1417.
19. [19] Macchia B., Balsamo A., Breschi M.C., Chiellini G., Lapucci A., Macchia M., Manera C., Martinelli A., Martini C., Scatizzi R., Uccello Barretta G., J. Med. Chem. 36 (1993) 3077-3086.
20. [20] Bylund D.B., Ray-Prenger C., Murphy T.J., J. Pharmacol. Exp. Ther. 259 (1988) 323-329.
21. [21] Blaxall H.S., Murphy T.J., Baker J.C., Ray C., Bylund D.B., J. Pharmacol. Exp. Ther. 259 (1991) 323-329.
22. [22] Berlie J.R., Iversen L.J., Blaxall H.S., Cooley M.E., Chacko D.M., Bylund D.B., Invest. Ophthalmol. Vis. Sci. 36 (1995) 1885-1892.
23. [23] Jones S.B., Halenda S.P., Bylund D.B., Mol. Pharmacol. 39 (1991) 239-245.
24. [24] Cerutis D.R., Deupree J.D., Heck D.A., Zhu S.-J., Toews M.L., Bylund D.B., In: Lanier S., Limbird L. (Eds.), Alpha-2 Adrenergic Receptors: Structure, Function and Therapeutic Implications, Gorden and Breach, London, UK, 1996, pp. 103-112.
25. [25] Blaxall H.S., Cerutis D.R., Hass N.A., Iversen L.J., Bylund D.B., Mol. Pharmacol. 45 (1994) 176-181.
26. [26] Ernsberger P., Meeley M.P., Mann J.J., Reis D.J., Eur. J. Pharmacol. 134 (1987) 1-13.
27. [27] Ernsberger P., Meeley M.P., Reis D.J., Brain Res. 441 (1988) 309-318.
28. [28] Ernsberger P., Feinland G., Evinger M.J., Meeley M.P., Reis D.J., Am. J. Hypertens. 2 (1989) 93A.
29. [29] Ernsberger P., Feinland G., Meeley M.P., Reis D.J., Am. J. Hypertens. 30 (1990) 90-97.
30. [30] Ernsberger P., Giuliano R., Wilette R.N., Reis D.J., J. Pharmacol. Exp. Ther. 253 (1990) 408-418.
31. [31] Cheng Y.C., Prusoff W.H., Biochem. Pharmacol. 22 (1973) 3099-3108.
32. [32] Macchia B., Balsamo A., Breschi M.C., Chiellini G., Macchia M., Martinelli A., Martini C., Nardini C., Nencetti S., Rossello A., Scatizzi R., J. Med. Chem. 37 (1994) 1518-1525.
33. [33] Bylund D.B., Ann. NY Acad. Sci. 763 (1995) 1-7.